Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed (Nasdaq: INSM) announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on BRINSUPRI (brensocatib 25 mg) on October 17, 2025, recommending approval for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older with two or more exacerbations in the prior 12 months.
BRINSUPRI was reviewed under the CHMP's accelerated assessment and had prior PRIME designation; the opinion is based on Phase 3 ASPEN and Phase 2 WILLOW data published in the New England Journal of Medicine. The European Commission will issue a final decision in the coming months.
Insmed (Nasdaq: INSM) will present six abstracts from the Phase 3 ASPEN trial of BRINSUPRI (brensocatib) at CHEST 2025 in Chicago, Oct 19–22, 2025. Presentations include prespecified and post‑hoc subgroup analyses, a late‑breaking high‑resolution CT substudy on structural lung changes, NSP (neutrophil serine protease) suppression data, and analyses of efficacy, symptom burden, and biomarker effects in patients with non‑cystic fibrosis bronchiectasis (NCFB).
Sessions cover COPD comorbidity, Asian population outcomes, BEST symptom assessments during and outside exacerbations, and multiple poster and oral presentations led by named investigators across Oct 20–22, 2025.
Insmed (Nasdaq: INSM) will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Management will host a conference call for investors at 8:00 a.m. ET the same day to discuss results and provide a business update.
Investors may dial (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189, or listen via live webcast at www.insmed.com. A replay will be available about one hour after the call through November 6, 2025 by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) with access code 7862189. The webcast will be archived for 90 days under the Investor Relations section of the company website.
Insmed (NASDAQ:INSM) will present seven abstracts from its late-stage portfolio at the European Respiratory Society (ERS) 2025 Congress from September 27 to October 1, 2025, in Amsterdam.
A key highlight includes data from the Phase 2b TPIP trial in pulmonary arterial hypertension patients, which will be featured in the prestigious ALERT session for late-breaking clinical data. Additionally, the company will present three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib, including Japanese patient data, and Health Outcomes Research from the THIN database focusing on non-cystic fibrosis bronchiectasis (NCFB) patients in France and the UK.
The presentations will take place across multiple sessions, including oral presentations and poster sessions, showcasing various aspects of their clinical research and patient outcomes.
Insmed (Nasdaq: INSM) has granted inducement awards to 115 new employees under its 2025 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, approved on August 29, 2025, include 70,742 restricted stock units and options to purchase 8,420 shares at $136.10 per share.
The restricted stock units feature a four-year vesting schedule with 25% vesting annually. The stock options have a 10-year term with 25% vesting after the first year and 12.5% vesting semi-annually for the following three years, subject to continued employment.
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5 at 8:00 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9 at 4:50 p.m. ET.
Both presentations will be available via webcast through Insmed's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM) has achieved a historic milestone with the FDA approval of BRINSUPRI™ (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. This first-in-class oral DPP1 inhibitor targets neutrophilic inflammation, a root cause of bronchiectasis exacerbations.
The approval is supported by Phase 3 ASPEN and Phase 2 WILLOW studies, showing significant clinical benefits: BRINSUPRI demonstrated a 21.1% reduction in annual exacerbation rates at 10mg and 19.4% at 25mg compared to placebo. The drug is now available in the U.S. through specialty pharmacies, addressing a market of approximately 500,000 diagnosed patients.
Insmed (Nasdaq: INSM) reported strong Q2 2025 financial results, with ARIKAYCE revenue reaching $107.4 million, up 19% year-over-year. The company maintained its 2025 ARIKAYCE revenue guidance of $405-425 million.
Key developments include: pending FDA approval for brensocatib in bronchiectasis (PDUFA date: August 12, 2025), positive Phase 2b results for TPIP in PAH, and Phase 3 studies planned for PH-ILD and PAH. The company reported a Q2 net loss of $321.7 million ($1.70 per share) and holds a strong cash position of $1.9 billion following a successful public offering that raised $823.1 million.
Insmed (Nasdaq: INSM) has scheduled its second-quarter 2025 financial results conference call for Thursday, August 7, 2025, at 8:00 a.m. ET. The company will release its financial results the same day.
Investors can join the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. A live webcast will be available on Insmed's website. The call replay will be accessible until August 14, 2025, and the webcast recording will be archived for 90 days on the company's investor relations website.